Cerebral aneurysm pathophysiology

Revision as of 04:10, 17 June 2022 by Anika (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Cerebral aneurysm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cerebral aneurysm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cerebral aneurysm pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cerebral aneurysm pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cerebral aneurysm pathophysiology

CDC on Cerebral aneurysm pathophysiology

Cerebral aneurysm pathophysiology in the news

Blogs on Cerebral aneurysm pathophysiology

Directions to Hospitals Treating Cerebral aneurysm

Risk calculators and risk factors for Cerebral aneurysm pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Anika Zahoor M.D.[2]

Overview

Genes involved in the pathogenesis of cerebral aneurysm include [gene1], [gene2], and [gene3]. The pathophysiology of [disease name] depends on the histological subtype.

Pathophysiology

Pathogenesis

Pathogenesis is the mechanism by which a certain factor causes disease (pathos = disease, genesis = development). The term can also be used to describe the development of the disease, whether it is acute, chronic, or recurrent. It can also be used to describe whether the disease causes inflammation, malignancy, necrosis etc.

Template Sentences

IF the pathogenesis of the disease is unclear:

  • It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either hypertension, collagen diseases, or [hypothesis 3].

IF the disease has a known genetic component:

  • [Disease name] is transmitted in [mode of genetic transmission] pattern.
  • Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].

IF certain pathology findings are characteristic of the disease:

  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Other relevant information may include the action of the pathogen on a molecular level, the body’s response, whether or not mutations play a role in the disease development, whether the pathophysiology of the disease is different among subgroups of the disease, etc. Additional template sentences are listed below. Due to the highly variable nature of pathophysiology among various diseases, this list is not comprehensive.

  • [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
  • The development of [disease name] is the result of multiple genetic mutations.
  • The progression to [disease name] usually involves the [molecular pathway].
  • The pathophysiology of [disease/malignancy] depends on the histological subtype.
  • For an example of a pathogenesis section within a pathophysiology page, click here

Pathological Findings

Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

References

1.Jung K. H. (2018). New Pathophysiological Considerations on Cerebral Aneurysms. Neurointervention, 13(2), 73–83. https://doi.org/10.5469/neuroint.2018.01011